NYSE:MCK - McKesson Stock Price, Forecast & News

McKesson's stock was trading at $135.17 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MCK stock has decreased by 7.0% and is now trading at $125.70. View which stocks have been mosted impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last year. There are currently 1 sell rating, 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for McKesson.

McKesson is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for McKesson.

McKesson Co. (NYSE:MCK) issued its quarterly earnings results on Tuesday, February, 4th. The company reported $3.81 earnings per share for the quarter, topping the consensus estimate of $3.56 by $0.25. The business had revenue of $59.17 billion for the quarter, compared to analyst estimates of $59.10 billion. McKesson had a negative net margin of 0.41% and a positive return on equity of 36.40%. The business's quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the business posted $3.40 EPS. View McKesson's earnings history.

McKesson declared a quarterly dividend on Wednesday, January 29th. Shareholders of record on Monday, March 2nd will be given a dividend of $0.41 per share on Wednesday, April 1st. This represents a $1.64 dividend on an annualized basis and a yield of 1.30%. The ex-dividend date of this dividend is Friday, February 28th. View McKesson's dividend history.

McKesson issued an update on its FY20 earnings guidance on Tuesday, March, 17th. The company provided EPS guidance of $14.67-14.87 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $14.74.

12 brokers have issued 12-month target prices for McKesson's shares. Their forecasts range from $140.00 to $197.00. On average, they expect McKesson's share price to reach $163.18 in the next twelve months. This suggests a possible upside of 29.8% from the stock's current price. View analysts' price targets for McKesson.

Press coverage about MCK stock has trended very positive on Saturday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. McKesson earned a daily sentiment score of 4.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutMcKesson.

McKesson saw a increase in short interest in March. As of March 13th, there was short interest totaling 36,482,200 shares, an increase of 93.4% from the February 27th total of 18,860,000 shares. Based on an average daily volume of 3,930,000 shares, the days-to-cover ratio is currently 9.3 days. Approximately 25.6% of the shares of the company are short sold. View McKesson's Current Options Chain.

Some companies that are related to McKesson include AmerisourceBergen (ABC), Cardinal Health (CAH), Henry Schein (HSIC), Patterson Companies (PDCO) and Owens & Minor (OMI).

Based on aggregate information from My MarketBeat watchlists, some companies that other McKesson investors own include Walt Disney (DIS), Gilead Sciences (GILD), salesforce.com (CRM), CVS Health (CVS), Allergan (AGN), UnitedHealth Group (UNH), Bank of America (BAC), AbbVie (ABBV), Chevron (CVX) and Intel (INTC).

McKesson trades on the New York Stock Exchange (NYSE) under the ticker symbol "MCK."

McKesson's stock is owned by a number of institutional and retail investors. Top institutional shareholders include State Street Corp (4.66%), Massachusetts Financial Services Co. MA (3.11%), FMR LLC (2.39%), Boston Partners (2.33%), Pzena Investment Management LLC (2.13%) and Geode Capital Management LLC (1.64%). Company insiders that own McKesson stock include Brian S Tyler, Brian Scott Tyler, Britt J Vitalone, Erin M Lampert, Lori A Schechter, M Christine Jacobs, N Anthony Coles and Sundeep G Reddy. View institutional ownership trends for McKesson.

MCK stock was sold by a variety of institutional investors in the last quarter, including Ruffer LLP, Massachusetts Financial Services Co. MA, Man Group plc, FMR LLC, PGGM Investments, Boston Partners, State Street Corp, and Assenagon Asset Management S.A.. Company insiders that have sold McKesson company stock in the last year include Brian S Tyler, Brian Scott Tyler, Britt J Vitalone, Lori A Schechter, M Christine Jacobs, and Sundeep G Reddy. View insider buying and selling activity for McKesson.

MCK stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, AQR Capital Management LLC, Amundi Pioneer Asset Management Inc., Investec Asset Management LTD, Baupost Group LLC MA, Jacobs Levy Equity Management Inc., Panagora Asset Management Inc., and Eaton Vance Management. View insider buying and selling activity for McKesson.

Shares of MCK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MCK stock can currently be purchased for approximately $125.70.

McKesson has a market capitalization of $22.24 billion and generates $214.32 billion in revenue each year. The company earns $34 million in net income (profit) each year or $13.57 on an earnings per share basis. McKesson employs 80,000 workers across the globe. View additional information about McKesson.

The official website for McKesson is http://www.mckesson.com/.

McKesson's mailing address is 6555 STATE HWY 161, IRVING TX, 75039. The company can be reached via phone at 972-446-4800 or via email at [email protected]